Explosive Growth Predicted for NASH Biomarkers Market Ahead
Austin, June 12, 2025 - The Non-alcoholic Steatohepatitis Biomarkers Market is forecasted to see remarkable growth, projected to reach USD 9.1 billion by 2032, up from USD 1.14 billion in 2023, with a noteworthy CAGR of 25.9% during the 2024-2032 period. This forecast reflects the increase of non-alcoholic fatty liver disease (NAFLD) prevalence, particularly the serious variant known as NASH, alongside a rising demand for non-invasive diagnostic tools.
Driving this growth are significant advancements in biomarker research, spurred by cutting-edge artificial intelligence (AI) diagnostic solutions and innovative biomarker assay techniques. The combination of enhanced diagnostic capabilities and increased awareness among health care providers and patients regarding the importance of early detection of NASH fuels the market's upward trajectory.
Market Overview
The increasing incidence of NASH, a severe form of NAFLD, highlights the urgent need for advanced and reliable diagnostic solutions. Traditional liver biopsies are being replaced due to their invasive nature, high costs, and associated risks. This shift has created a strong demand for non-invasive, biomarker-based diagnostics.
With rising rates of obesity, metabolic syndrome, and diabetes contributing to the increasing pool of NASH patients, the reliance on diagnostic breakthroughs is more important than ever. Leaders in the industry are focusing on the development of AI-driven biomarker assays, along with innovative proteomic and metabolomic strategies aimed at improving NASH detection and management.
Key Players Shaping the Market
The following industry leaders are making significant strides in the NASH biomarkers landscape:
- GENFIT (NIS4™, Elafibranor)
- Gilead Sciences (Selonsertib, Cilofexor)
- AstraZeneca (Dapagliflozin, Epanova)
- Novartis AG (Tropifexor, LJN452)
- GE Healthcare (LiverMultiScan, FibroScan)
- Siemens Healthineers (ADVIA Centaur® CP Immunoassay System, Atellica® Solution)
- Bristol-Myers Squibb (Pegbelfermin, BMS-986036)
- Pfizer Inc. (PF-06865571, PF-05221304)
- Akero Therapeutics (Efruxifermin, AKR-001)
- 89bio (Pegozafermin, BIO89-100)
Segment Analysis
Type Segmentation
The serum biomarkers segment dominated the market in 2023, accounting for 33% of the total revenue. These biomarkers, which include liver enzyme panels and inflammatory markers, are favored for their accuracy and ease of use. The demand for non-invasive diagnostic methods and AI-integrated algorithms is contributing to the growth of this market segment.
Among the various types, apoptosis biomarkers are anticipated to witness the highest growth, particularly cytokeratin-18 (CK-18), which provides insights into hepatocyte death and aids in tracking disease progression.
End-Use Market
The pharmaceutical and clinical research organization (CRO) segment captured the largest market share in 2023 at 39%. This is attributed to pharmaceutical companies' increasing reliance on biomarker-based strategies to enhance drug discovery and streamline clinical trials. With numerous candidates for NASH in advanced clinical stages, the CROs are vital in validating biomarkers and speeding up the approval process.
Additionally, the diagnostic laboratory segment is expected to grow rapidly as the demand for sophisticated and non-invasive diagnostic solutions surges. Healthcare professionals and patients alike are increasingly recognizing the critical importance of early NASH diagnosis, propelling this segment forward.
Spotlighting Global Growth Trends
In 2023, North America was the frontrunner in the NASH biomarkers market, accounting for 40% of the total share. This dominance can be traced back to robust healthcare infrastructure and a high incidence of obesity and metabolic disorders within the region. Furthermore, the presence of major pharmaceutical and diagnostics firms continues to stimulate market expansion.
The Asia Pacific is forecasted to experience the highest growth in the coming years. Increasing incidences of NAFLD and NASH, along with the escalation of healthcare investments and innovative diagnostic techniques, are significantly contributing to this growth potential.
Recent Developments in the Field
Recent innovations include advancements made by industry leaders in developing next-generation assays that utilize AI for greater diagnostic precision. Companies like Siemens Healthineers and AstraZeneca are at the forefront of integrating multiple data types for the advancement of personalized treatment options for NASH.
Frequently Asked Questions
What is the current market size for NASH biomarkers?
The current market size for NASH biomarkers is estimated to be USD 1.14 billion in 2023.
What growth rate is expected for the NASH biomarkers market?
The market is projected to grow at a CAGR of 25.9% from 2024 to 2032.
Who are the major players in the NASH biomarkers market?
Major players include GENFIT, Gilead Sciences, AstraZeneca, and Novartis AG, among others.
What factors are driving market growth?
The rise in NASH prevalence, demand for non-invasive diagnostics, and advancements in biomarker research are key growth drivers.
Which region is leading in the NASH biomarkers market?
North America currently leads the NASH biomarkers market, followed by significant growth expected in the Asia Pacific region.
